Skip to main content Accessibility help
×
Hostname: page-component-84b7d79bbc-g5fl4 Total loading time: 0 Render date: 2024-07-26T02:35:09.187Z Has data issue: false hasContentIssue false

91 - Mirtazapine

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Remeron, Remeron SolTab

Generic?

• Yes

Class

• Tetracyclic antidepressant

Commonly Prescribed for

(FDA approved in bold)

Major depressive disorder

• Tension-type headache prophylaxis

• Post-traumatic stress disorder (PTSD)

• Panic disorder

• Fibromyalgia

• Neuropathic pain

• Phantom limb pain

• Antiemetic

How the Drug Works

• Mirtazapine enhances central noradrenergic and serotonergic activity via presynaptic α2-receptor blockade. Mirtazapine is an antagonist of 5-HT2, 5-HT3, H1, α1-, α2- adrenergic, and muscarinic receptors. Mirtazapine has no significant affinity for the 5-HT1A and 5-HT1B receptors

How Long Until It Works

• Depression: 2 weeks but up to 2 months for full effect

If It Works

• Continue to use and monitor for AEs. May continue for 1 year following first depression episode or indefinitely if> 1 episode of depression

If It Doesn't Work

• Increase to highest tolerated dose. Change to another agent or add a second agent

Best Augmenting Combos for Partial Response or Treatment-Resistance

• For some patients, low-dose polytherapy with 2 or more drugs may be better tolerated and more effective than high-dose monotherapy

Tests

• Monitor transaminase, serum sodium, and CBC

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Through serotonin, histamine, adrenergic, muscarinic receptor antagonism throughout the body. Most AEs are dose- and timedependent

Notable AEs

• Somnolence, dizziness, constipation, dry mouth, increased appetite, weight gain, increased cholesterol, akathisia

Life-Threatening or Dangerous AEs

• Serotonin syndrome

• Rare hepatitis

• Rare activation of mania or suicidal ideation

• Rare worsening of coexisting seizure disorders

• Hyponatremia

• Agranulocytosis

Weight Gain

• Problematic

Sedation

• Common

What to Do About AEs

• For minor AEs, lower dose, titrate more slowly, or switch to another agent. For serious AEs, lower dose and consider stopping, taper to avoid withdrawal symptoms

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 335 - 337
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Mirtazapine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.092
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Mirtazapine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.092
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Mirtazapine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.092
Available formats
×